EXELON rivastigmine tartrate capsule

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

RIVASTIGMINE TARTRATE (UNII: 9IY2357JPE) (RIVASTIGMINE - UNII:PKI06M3IW0)

Disponible des:

Avera McKennan Hospital

Designació comuna internacional (DCI):

RIVASTIGMINE TARTRATE

Composición:

RIVASTIGMINE 3 mg

tipo de receta:

PRESCRIPTION DRUG

Estat d'Autorització:

New Drug Application

Fitxa tècnica

EXELON- RIVASTIGMINE TARTRATE CAPSULE
AVERA MCKENNAN HOSPITAL
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
EXELON SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR EXELON.
EXELON (RIVASTIGMINE TARTRATE) CAPSULES, FOR ORAL USE
INITIAL U.S. APPROVAL: 2000
INDICATIONS AND USAGE
EXELON is an acetylcholinesterase inhibitor indicated for treatment
of:
Mild to moderate dementia of the Alzheimer’s type (AD) (1.1)
Mild to moderate dementia associated with Parkinson’s disease (PDD)
(1.2)
DOSAGE AND ADMINISTRATION
Alzheimer’s Disease (2.1):
Initial Dose: Initiate treatment with 1.5 mg twice a day.
Dose Titration: After a minimum of 2 weeks, if tolerated, increase
dose to 3 mg twice a day and further to 4.5 mg twice a
day and 6 mg twice a day if tolerated with a minimum of 2 weeks at
each dose
Parkinson’s Disease Dementia (2.2):
Initial Dose: Initiate treatment with 1.5 mg twice a day.
Dose Titration: After a minimum of 4 weeks, if tolerated, increase
dose to 3 mg twice a day and further to 4.5 mg twice a
day and 6 mg twice a day if tolerated with a minimum of 4 weeks at
each dose.
EXELON should be taken with meals in divided doses in the morning and
evening. (2.1, 2.2). EXELON Oral Solution and
EXELON Capsules may be interchanged at equal doses (2.5)
DOSAGE FORMS AND STRENGTHS
Capsules: 1.5 mg, 3 mg, 4.5 mg, or 6 mg (3.1)
Oral solution: 2 mg/mL (3.2)
CONTRAINDICATIONS
Known hypersensitivity to rivastigmine, other carbamate derivatives or
other components of the formulation. (4)
History of application site reaction with rivastigmine transdermal
patch suggestive of allergic contact dermatitis, in the
absence of negative allergy testing. (4, 5.2)
WARNINGS AND PRECAUTIONS
Gastrointestinal adverse reactions may include significant nausea,
vomiting, diarrhea, anorexia/decreased appetite, and
weight loss, and may necessitate treatment interruption. Dehydration
may result from prolonged vomiting or diarrhea
and can be associated with serious ou